AbCellera Biologics (ABCL) Change in Acquisitions & Divestments (2021 - 2026)

AbCellera Biologics has reported Change in Acquisitions & Divestments for 6 years, with the latest figure at $143.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 24.33% year-over-year to $143.8 million; the trailing twelve-month figure through Mar 2026 stood at $459.8 million (down 44.01% YoY), and the FY2025 full-year result was $506.1 million, down 46.04% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $143.8 million, up from $119.5 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $306.5 million in Q1 2024, with the low at $57.3 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $177.0 million across 5 years, with a median of $190.0 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments jumped 410.99% — and 2025, when it slumped 57.73%.
• AbCellera Biologics' Change in Acquisitions & Divestments stood at $92.4 million in 2022, then jumped by 190.09% to $268.0 million in 2023, then retreated by 24.67% to $201.9 million in 2024, then sank by 40.79% to $119.5 million in 2025, then increased by 20.3% to $143.8 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $143.8 million (Q1 2026), $119.5 million (Q4 2025), and $83.1 million (Q3 2025), per Business Quant data.